Back to search results

Database Study on Medullary Thyroid Carcinoma Risk

This study is looking at whether certain medicines called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists), used for type 2 diabetes and weight management, might be linked to a rare cancer called medullary thyroid carcinoma (MTC). Researchers will compare how often MTC occurs in people taking these medicines versus those taking other similar treatments. This study uses existing health records and cancer registry data, so no new treatments are given. You could be included if you are 18 or older, have taken certain medications, and meet other criteria related to your prescription history. The main goal is to see how long it takes for MTC to occur, if it does, over a period of up to 15 years. The study is currently unclear on its status and aims to include a very large number of people.

Study design
This is an observational study that uses existing health records and cancer registry data. It is not testing a new treatment and does not involve direct patient participation.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track the time to the first occurrence of Medullary Thyroid Carcinoma (MTC) for up to 15 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07713901

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Enrolling by Invitation
Not specifiedAges 18+Observational
Novo Nordisk A/S
~93,600,000 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:No treatment given

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to first occurence of Medullary Thyroid Carcinoma (MTC)
Measured over From day 1 up to 15 years

Conditions

Medullary Thyroid Carcinoma

Explore related trials

Thyroid Gland Medullary Carcinoma

Where it's being run

1 sites across 1 states
New Jersey1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older during the year of index (date of qualifying medication)
In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
No evidence of cohort qualifying medication during 12-month before the index date
Reside in the US, including the District of Columbia (DC) during the study period
No missing values for year of birth

Exclusion

Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.

What this trial measures

  • Time to first occurence of Medullary Thyroid Carcinoma (MTC)From day 1 up to 15 years

    Measured in number of days.